22:54 , Aug 1, 2019 |  BC Innovations  |  Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
23:20 , Jul 26, 2019 |  BC Extra  |  Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

Obsidian Therapeutics (Cambridge, Mass.) hired Catherine Stehman-Breen as chief development officer, Ryan Daws as CFO, and Karen Brown as SVP, intellectual property and legal affairs. Stehman-Breen was CMO of Atlas Venture-backed Dyne Therapeutics Inc. (Cambridge,...
22:01 , Oct 4, 2018 |  BC Innovations  |  Tools & Techniques

Lilly: academic about manufacturing

As Eli Lilly and Co. moves toward continuous manufacturing, the pharma is deepening ties with two academic centers to meet an array of engineering challenges. Through partnerships with Carnegie Mellon University, and the U.K.’s Imperial...
23:03 , Nov 10, 2016 |  BC Innovations  |  Tools & Techniques

A different horse in the race

The nucleases at the heart of gene editing systems such as CRISPR, TALENs and zinc finger nucleases (ZFNs) are key to the methods’ strength, forming a fundamental part of the blocking IP. A group at...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Active machine learning algorithm to improve the efficiency of drug discovery

N/A TECHNOLOGY: Computational models An active machine learning algorithm that links compounds to intracellular protein localization patterns could improve the efficiency of drug discovery. The algorithm utilized automated sample-handling and microscopic techniques on murine embryonic...
08:00 , Feb 18, 2016 |  BC Innovations  |  Translation in Brief

Robot overlords

Researchers at Carnegie Mellon University are training computers to decide which preclinical experiments will result in the best predictions for how compounds interact with proteins, cells and genes. Having shown the algorithms can improve efficiency...
08:00 , Dec 21, 2015 |  BioCentury  |  Politics, Policy & Law

Trans-Pacific dreams

If Republicans in Congress move past their disappointment with biologics exclusivity provisions and ratify the Trans-Pacific Partnership trade treaty, the stage will be set for a significant strengthening of global IP protections for pharmaceuticals. The...
07:00 , May 19, 2014 |  BioCentury  |  Regulation

Getting to certain

As FDA moves closer to installing a new risk-benefit framework for drug reviews, it still is grappling with how to address uncertainties in the process. Last week, the agency and the Institute of Medicine concluded...
07:00 , Sep 26, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models A computational model to reconstruct network effects of microRNAs and identify targets A computational model that reconstructs dynamic network effects of...
08:00 , Feb 9, 2012 |  BC Innovations  |  Targets & Mechanisms

HUS and them

Two groups have identified new strategies to treat or prevent hemolytic uremic syndrome, a potentially lethal complication of Escherichia coli infection. A team at the University of Toronto has suggested that the marketed CXC chemokine...